I
Indira Warrier
Researcher at Boston Children's Hospital
Publications - 16
Citations - 2243
Indira Warrier is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Haemophilia B & Thrombocytopenic purpura. The author has an hindex of 12, co-authored 16 publications receiving 2194 citations.
Papers
More filters
Journal ArticleDOI
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
James N. George,Steven H. Woolf,Gary E. Raskob,Jeffrey S. Wasser,Louis M. Aledort,P. J. Ballem,Victor S. Blanchette,James B. Bussel,Douglas B. Cines,John G. Kelton,Alan E. Lichtin,Robert McMillan,JA Okerbloom,David H. Regan,Indira Warrier +14 more
TL;DR: This report begins with a brief summary of the panel’s recommendations, followed by a more detailed analysis of its methodology, the findings of the comprehensive literature review, and a full presentation of the recommendations.
Journal ArticleDOI
Plasma and albumin-free recombinant factor VIII: Pharmacokinetics, efficacy and safety in previously treated pediatric patients
Victor S. Blanchette,Amy D. Shapiro,R. Liesner,F Hernández Navarro,Indira Warrier,Phillip Schroth,Gerald Spotts,Bruce M. Ewenstein +7 more
TL;DR: In this article, the authors evaluated the pharmacokinetics, efficacy and safety of a plasma-free recombinant FVIII concentrate, ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, rAHF-PFM], in children < 6 years of age with severe hemophilia.
Journal ArticleDOI
Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B
Bruce M. Ewenstein,Clifford M. Takemoto,Indira Warrier,Jeanne M. Lusher,P. Saidi,J. Eisele,L. J. Ettinger,Donna DiMichele +7 more
TL;DR: To the Editor: Inhibitors to factor IX (fIX) develop in approximately 1.5% to 3% of persons with severe hemophilia B and are commonly associated with the complete absence of fIX antigen due to large gene deletions or nonsense mutations.
Journal ArticleDOI
The overall effectiveness of prophylaxis in severe haemophilia
TL;DR: By preventing new target joints, prophylaxis can lead to reduction in long‐term morbidity and a better quality of life despite increased central lines and higher factor usage.
Journal ArticleDOI
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Erik C. Thorland,Joni B. Drost,Jeanne M. Lusher,Indira Warrier,Amy D. Shapiro,Marion A. Koerper,Donna DiMichele,J. Westman,Nigel S. Key,Steve S. Sommer,Steve S. Sommer +10 more
TL;DR: The very high risk of anaphylaxis associated with a complete gene deletion suggests that the lack of expression of a partial protein product may predispose to anphylaxis and/or that the absence of a closely linked, codeleted gene enhances the anaphyactic immune response.